BB Biotech Q3 net profit falls, NAV underperforms biotech index

Bb Biotech AG

Today 06:17

Overview
Switzerland investment firm's Q3 net profit fell yr/yr as NAV underperformed biotech index
Three portfolio companies received US drug approvals during the quarter
Proceeds from two M&A deals were redeployed into twelve new positions

Outlook
BB Biotech expects further clinical and regulatory milestones across its portfolio in Q4
Company sees selective opportunities in companies with share price declines but unchanged clinical prospects
BB Biotech says sustained NAV performance relative to benchmark remains its investment progress measure

Result Drivers
CLINICAL PROGRESS - Three portfolio companies received US drug approvals in Q3, with additional positive clinical trial results reported across the portfolio
PORTFOLIO REDEPLOYMENT - Proceeds from two M&A transactions totaling CHF 280 mln were reinvested into twelve new positions spanning commercial-stage, clinical-stage and private companies
ACTIVE POSITION MANAGEMENT - Higher portfolio activity reflected completed acquisitions and valuation-driven adjustments, with eight positions exited and rebuilding of selected holdings at lower valuations

Company press release: ID:nEQ5T5pZpa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
 
CHF 175 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the investment management & fund operators peer group is "buy"
The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 23 three months ago

Reuters Recommended Reads
Oct 22 - Roche beats revenue estimates, shares slip as copycats eat into Xolair sales
Oct 22 - Galderma lifts outlook for second quarter in a row after sales jump
Oct 22 - Netherlands' Argenx Q3 sales jump on strong VYVGART demand 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)